Literature DB >> 24217666

Profile of paediatric rheumatology specialists and services in the state of São Paulo.

Maria Teresa Terreri, Lúcia M A Campos, Eunice M Okuda, Clovis A Silva, Silvana B Sacchetti, Roberto Marini, Virginia P Ferriani, Maria Heloiza Ventura, Taciana Fernandes, Juliana O Sato, Elizabeth C Fernandes, Claudio Len, Cássia Barbosa, Ana Paola Lotito, Maria Carolina dos Santos, Nádia E Aikawa, Mércia Facó, Daniela Piotto, Vanessa Bugni, Kátia T Kozu, Paulo R Romanelli, Adriana M E Sallum, Marília Febronio, Melissa Fraga, Cláudia S Magalhães.   

Abstract

INTRODUCTION: Paediatric rheumatology (PR) is an emerging specialty, practised by a limited number of specialists. Currently, there is neither a record of the profile of rheumatology patients being treated in Brazil nor data on the training of qualified rheumatology professionals in the country.
OBJECTIVE: To investigate the profile of PR specialists and services, as well as the characteristics of paediatric patients with rheumatic diseases, for estimating the current state of rheumatology in the state of São Paulo. PATIENTS AND METHODS: In 2010, the scientific department of PR of the Paediatric Society of São Paulo administered a questionnaire that was answered by 24/31 accredited specialists in PR practising in state of São Paulo and by 8/21 institutions that provide PR care.
RESULTS: Most (91%) of the surveyed professionals practise in public institutions. Private clinics (28.6%) and public institutions (37.5%) reported not having access to nailfold capillaroscopy, and 50% of the private clinics reported not having access to acupuncture. The average duration of professional practise in PR was 9.4 years, and 67% of the physicians had attended postgraduate programmes. Seven (87.5%) public institutions perform teaching activities, in which new paediatric rheumatologists are trained, and five (62.5%) offer postgraduate programmes. Two-thirds of the surveyed specialists use immunosuppressants and biological agents classified as "restricted use" by the Health Secretariat. The disease most frequently reported was juvenile idiopathic arthritis (29.1-34.5%), followed by juvenile systemic lupus erythematosus (JSLE) (11.6-12.3%) and rheumatic fever (9.1-15.9%). The incidence of vasculitis (including Henoch-Schönlein purpura, Wegener's granulomatosis, and Takayasu's arteritis) and autoinflammatory syndromes was higher in public institutions compared to other institutions (P = 0.03, P = 0.04, P = 0.002, and P < 0.0001, respectively). Patients with JSLE had the highest mortality rate (68% of deaths), mainly due to infection.
CONCLUSION: The field of PR in the state of São Paulo has a significant number of specialists with postgraduate degrees who mostly practise at teaching institutions with infrastructures appropriate for the care of high-complexity patients.

Entities:  

Mesh:

Year:  2013        PMID: 24217666

Source DB:  PubMed          Journal:  Rev Bras Reumatol        ISSN: 0482-5004


  3 in total

1.  Vitamin D levels in juvenile idiopathic arthritis from an equatorial region.

Authors:  Sâmia Araújo de Sousa Studart; Ana Caroline Rocha Melo Leite; Aryana Lushese Lima Feitosa Marinho; Ana Carolina Matias Dinelly Pinto; Carlos Nobre Rabelo Júnior; Rodolfo de Melo Nunes; Hermano Alexandre Lima Rocha; Francisco Airton Castro Rocha
Journal:  Rheumatol Int       Date:  2015-05-20       Impact factor: 2.631

2.  Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center.

Authors:  Izabel M Buscatti; Beatriz B Casella; Nadia E Aikawa; Andrea Watanabe; Sylvia C L Farhat; Lucia M A Campos; Clovis Artur Silva
Journal:  Clin Rheumatol       Date:  2018-01-13       Impact factor: 2.980

3.  Evaluation of disease activity in a low-income juvenile idiopathic arthritis cohort.

Authors:  Francisco Airton Castro Rocha; Joaquim Ivo Vasques Dantas Landim; Marcela Gondim Aguiar; João Pedro Emrich Accioly; Carolina Noronha Lechiu; Luiza Helena Acácio Costa; Carlos Nobre Rabelo Júnior; Leila Nascimento da Rocha; Hermano Alexandre Lima Rocha
Journal:  Rheumatol Int       Date:  2018-08-13       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.